Myocardial regeneration is an exciting new frontier for the treatment of heart disease. Many approaches are currently being tested. The use of autologous skeletal myoblasts has been the earliest, with over 10 years of...Myocardial regeneration is an exciting new frontier for the treatment of heart disease. Many approaches are currently being tested. The use of autologous skeletal myoblasts has been the earliest, with over 10 years of research having been conducted. Current progress in the area of skeletal myoblasts for cardiac regeneration is presented. Reviewed is work from both pre-clinical and clinical studies. Work in this area continues to progress and definitive studies to assess efficacy of myoblasts for heart failure either have been initiated or will be initiated shortly. One result that is clear is that myoblasts can survive and form myotubes and myofibers in the area of myocardial infarction. In the early clinical trials, arrhythmia was a concern. However, further studies have shown that the risk was assumed prematurely based on limited human studies. Myoblasts, therefore, provide a highly promising treatment for heart disease.展开更多
The aim of this prospective observational pilot study was to observe the impact of orbital atherectomy (OA) on the coronary microcirculation via coronary flow reserve (CFR) measurements. Fifteen subjects who had succe...The aim of this prospective observational pilot study was to observe the impact of orbital atherectomy (OA) on the coronary microcirculation via coronary flow reserve (CFR) measurements. Fifteen subjects who had successful OA and stent placement with no procedural complication were enrolled at 3 hospitals in the U.S. Baseline and hyperemic velocities were 16 ± 5.2 and 36 ± 14 cm/sec, respectively. The average CFR post-procedure was within the normal range at 2.23 ± 0.33. The observation of normal CFR following OA may be attributed to the orbital action of the device that allows for continuous flow during treatment, minimizing a bolus embolization effect which can impact microvascular function.展开更多
文摘Myocardial regeneration is an exciting new frontier for the treatment of heart disease. Many approaches are currently being tested. The use of autologous skeletal myoblasts has been the earliest, with over 10 years of research having been conducted. Current progress in the area of skeletal myoblasts for cardiac regeneration is presented. Reviewed is work from both pre-clinical and clinical studies. Work in this area continues to progress and definitive studies to assess efficacy of myoblasts for heart failure either have been initiated or will be initiated shortly. One result that is clear is that myoblasts can survive and form myotubes and myofibers in the area of myocardial infarction. In the early clinical trials, arrhythmia was a concern. However, further studies have shown that the risk was assumed prematurely based on limited human studies. Myoblasts, therefore, provide a highly promising treatment for heart disease.
文摘The aim of this prospective observational pilot study was to observe the impact of orbital atherectomy (OA) on the coronary microcirculation via coronary flow reserve (CFR) measurements. Fifteen subjects who had successful OA and stent placement with no procedural complication were enrolled at 3 hospitals in the U.S. Baseline and hyperemic velocities were 16 ± 5.2 and 36 ± 14 cm/sec, respectively. The average CFR post-procedure was within the normal range at 2.23 ± 0.33. The observation of normal CFR following OA may be attributed to the orbital action of the device that allows for continuous flow during treatment, minimizing a bolus embolization effect which can impact microvascular function.
